H.C. Wainwright analyst Robert Burns raised the firm’s price target on Exelixis (EXEL) to $49 from $46 and keeps a Buy rating on the shares following the Q3 report. The firm sees the key value driver for the shares as sentiment on the commercial future for zanzalintinib across various tumor types.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EXEL:
- Exelixis price target raised to $51 from $44 at TD Cowen
- Exelixis price target raised to $43 from $41 at Stifel
- Exelixis price target raised to $41 from $40 at Barclays
- Exelixis’s Strong Financial Performance and Growth Prospects Earns Buy Rating from Yaron Werber
- Exelixis Reports Strong Q3 2025 Financial Results